返回
Abivax SA（ABVX）價格
ABVX 股價走勢圖
ABVX 收益
Abivax SA
$117.1
0.25%
$0.29
收盤價：Jan 16, 16:00:00 GMT-5
$116.93
-0.14%
$-0.16
盤後：Jan 16, 20:00:00 GMT-5
關鍵數據
前收市價
$116.8
開盤價
$116.79
當日範圍
$116.02 - $119.24
52週區間
$4.77 - $148.83
交易量
777.2K
平均成交量
1.6M
每股盈餘 (TTM)
-3.62
股息收益率
--
市值
$9.1B
什麼是 ABVX？
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.